Investment Rating - The industry investment rating is "Outperform the Market," indicating that the industry index is expected to perform better than the market by more than 5% over the next six months [31]. Core Insights - The JPMorgan Healthcare Conference highlighted six top candidate drugs in the Chinese market for 2026, with four originating from local innovative companies, showcasing their R&D capabilities that can compete with multinational brands [4]. - The report anticipates continued active merger and acquisition (M&A) transactions in the biopharmaceutical sector, with a projected global M&A transaction volume reaching $5.1 trillion in 2025, led by a 44% increase in the healthcare sector [4]. - Investment strategies suggest focusing on innovative Chinese pharmaceutical companies that are enhancing their global competitiveness, particularly in therapeutic areas like metabolism, chronic diseases, and central nervous system disorders, as well as potential technology platforms such as small nucleic acid drugs and CAR-T therapies [5]. Summary by Sections Industry Overview - The JPMorgan Healthcare Conference showcased 24 Chinese innovative pharmaceutical companies, including BeiGene and Legend Biotech, presenting their latest R&D and commercialization achievements [4]. - The report emphasizes the importance of the Chinese market, identifying six candidate drugs that are expected to make significant impacts in 2026 [4]. Investment Strategy - The report recommends focusing on innovative therapeutic areas beyond traditional oncology and immunology, such as metabolic disorders and chronic diseases [5]. - It also highlights the potential of emerging technology platforms, suggesting investment in companies that are advancing in areas like peptide drugs and small nucleic acids [5]. Market Performance - The pharmaceutical sector experienced a decline of 0.68% last week, while the Shanghai and Shenzhen 300 Index fell by 0.57%, ranking the pharmaceutical industry 17th among 27 sectors [20]. - In contrast, the Hong Kong pharmaceutical sector saw an increase of 2.38%, outperforming the Hang Seng Index, which rose by 2.56%, ranking 6th among 11 sectors [30].

格隆汇1月21日丨荣昌生物(09995.HK)发布公告，2026年1月20日耗资人民币2000.4万元回购19.41万股A 股，回购价格每股102.17-103.78元。 截至2026年1月20日，公司已透过上交所的交易系统以集中竞价交易方式累计回购19.41万股公司股份， 占公司股本总数的0.0344%。回购交易的最高价格为每股人民币103.78元、最低价格为每股人民币 102.17元，所付资金总额为人民币2000.4万元(不包括交易费用)。公司的股份回购已达回购资金总额的 下限，且并无超越回购资金总额的上限，回购计划已完全实施。 ...

截至2026年1月20日，本公司已透过上海证券交易所的交易系统以集中竞价交易方式累计回购19.41万股 本公司股份，占本公司股本总数的0.0344%。回购交易的最高价格为每股人民币103.78元、最低价格为 每股人民币102.17元，所付资金总额为人民币2000.4万元(不包括交易费用)。本公司的股份回购已达回 购资金总额的下限，且并无超越回购资金总额的上限，回购计划已完全实施。 荣昌生物(09995)发布公告，于2026年1月20日，本公司透过上海证券交易所的交易系统以集中竞价交易 方式首次回购19.41万股本公司股份，占本公司股本总数5.64亿股的0.0344%。回购交易的最高价格为每 股人民币103.78元、最低价格为每股人民币102.17元，所付资金总额为人民币2000.4万元(不包括交易费 用)。 ...

截至2026年1月20日，本公司已透过上海证券交易所的交易系统以集中竞价交易方式累计回购19.41万股 本公司股份，占本公司股本总数的0.0344%。回购交易的最高价格为每股人民币103.78元、最低价格为 每股人民币102.17 元，所付资金总额为人民币2000.4万元(不包括交易费用)。本公司的股份回购已达回 购资金总额的下限，且并无超越回购资金总额的上限，回购计划已完全实施。 智通财经APP讯，荣昌生物(09995)发布公告，于2026年1月20日，本公司透过上海证券交易所的交易系 统以集中竞价交易方式首次回购19.41万股本公司股份，占本公司股本总数5.64亿股的 0.0344%。回购交 易的最高价格为每股人民币103.78元、最低价格为每股人民币102.17元，所付资金总额为人民币2000.4 万元(不包括交易费用)。 ...

截至2026年1月20日，公司已透过上交所的交易系统以集中竞价交易方式累计回购19.41万股公司股份， 占公司股本总数的0.0344%。回购交易的最高价格为每股人民币103.78元、最低价格为每股人民币 102.17元，所付资金总额为人民币2000.4万元(不包括交易费用)。公司的股份回购已达回购资金总额的 下限，且并无超越回购资金总额的上限，回购计划已完全实施。 格隆汇1月21日丨荣昌生物(09995.HK)发布公告，2026年1月20日耗资人民币2000.4万元回购19.41万股A 股，回购价格每股102.17-103.78元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 榮昌生物製藥（煙台）股份有限公司 呈交日期： 2026年1月20日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | 688331 | 說明 | 在上海證券交易所上市 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因依賴該等 內容而引致的任何損失承擔任何責任。 RemeGen Co., Ltd.* 榮 昌 生 物 製 藥（ 煙 台 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：9995） 有關首次股份回購及完成股份回購計劃的公告 茲提述榮昌生物製藥（煙台）股份有限公司（「本公司」）日期為2025年12月15日及 2026年1月15日的公告（「該等公告」）。除另有界定者外，本公告所用詞彙與該等 公告中所界定者具有相同涵義。 在本次股份回購過程中，本公司嚴格按照相關法例和法規回購本公司股份， 符合《上市公司股份回購規則》、《上海證券交易所上市公司自律監管指引第7 號 — 回購股份》及其他相關法規和本公司的股份回購計劃。回購計劃的實際 實施過程與原本披露的回購計劃並無分別。本公司已根據所披露的計劃完成 回購。 實施股份回購所用的資金為本公司的自有及╱或自籌資金，對本公司的經 營活動、財務狀況及未來發展不會有重大影響。本次股份回購不會導致 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688331 证券简称：荣昌生物 公告编号：2026-004 荣昌生物制药（烟台）股份有限公司 关于首次回购股份暨回购股份方案实施完成的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ■ 一、回购审批情况和回购方案内容 荣昌生物制药（烟台）股份有限公司（以下简称"公司"）于2025年12月15日召开第二届董事会第三十二 次会议，审议通过了《关于以集中竞价交易方式回购公司股份方案的议案》。同意公司使用自有资金 和/或自筹资金以集中竞价交易方式回购公司已发行的部分人民币普通股（A股）股票，拟回购资金总额 不低于人民币2,000万元（含）且不超过人民币4,000万元（含），回购的股份将在未来合适的时机用于 员工持股计划或股权激励，回购价格不超过人民币95元/股（含），回购股份期限为自公司董事会审议 通过本次回购方案之日起12个月内。 具体内容详见公司于2025年12月16日、2025年12月23日在上海证券交易所网站（www.sse.com.cn）披露 ...

Core Viewpoint - Rongchang Biologics (688331) announced its first share buyback on January 20, 2023, indicating confidence in its stock value and commitment to returning capital to shareholders [1] Group 1: Share Buyback Details - The company repurchased 194,100 shares, which represents 0.0344% of its total share capital [1] - The highest price paid for the shares was 103.78 yuan per share, while the lowest price was 102.17 yuan per share [1] - The total amount spent on the buyback was 20.004 million yuan, excluding transaction fees [1] Group 2: Buyback Plan Status - The buyback has reached the lower limit of the planned total expenditure and has not exceeded the upper limit [1] - The implementation of the buyback plan is now complete [1]

Core Viewpoint - The A-share market is experiencing fluctuations, particularly affecting the innovative drug sector, with the ETF Huatai Innovation Drug (589120) declining by 2.05% and facing a five-day losing streak, despite attracting over 7.9 million yuan in funds [1][3]. Group 1: Market Performance - The Huatai Innovation Drug ETF (589120) has seen a decline in its constituent stocks, with major players like I-Mab and Junshi Biosciences dropping over 3%, and others like BeiGene and Zai Lab falling more than 2% [3]. - The top ten constituent stocks of the ETF show a negative trend, with BeiGene-U down by 2.38% and Junshi Biosciences-U down by 3.42%, indicating a general downturn in the sector [3]. Group 2: Long-term Outlook - Despite the short-term market pressure, the long-term outlook for the innovative drug sector remains positive, with expectations of a clear beta market driven by liquidity recovery at the beginning of the year [4]. - The JPM conference highlighted the achievements of over 20 Chinese pharmaceutical companies, with projections for significant revenue growth in innovative drugs, such as a 25% increase for Heng Rui in 2026 [4]. Group 3: Business Development (BD) Trends - The BD activities in the sector are at a peak, with 17 transactions occurring since January, totaling approximately 10.15 billion USD in upfront payments, significantly exceeding market expectations [5]. - The ongoing trend of foreign companies expanding in China and the increasing flow of funds into the innovative drug sector suggest a favorable environment for growth and investment [5]. Group 4: Investment Strategy - The innovative drug sector is recommended for increased allocation, particularly in Hong Kong stocks, as the market is currently at a relative bottom, with potential for new historical highs [5]. - The ETF focuses on leading innovative drug companies, providing a high degree of exposure to the opportunities presented by the rise of Chinese innovative drugs [5].